Document
false0001574774 0001574774 2020-05-08 2020-05-08


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): May 8, 2020
https://cdn.kscope.io/c53d24e057f94497befaff6f866b85be-logo1a05.jpg
BioTelemetry, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-55039
 
46-2568498
(State or other jurisdiction
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification No.)
 
1000 Cedar Hollow Road
 
 
Malvern,
Pennsylvania
 
19355
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (610) 729-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
BEAT
NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     
 





Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 8, 2020, BioTelemetry, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders adopted the following proposals and cast their votes as described below.
Proposal 1
Election of three Class I director nominees to hold office until the 2023 Annual Meeting of Stockholders or until their successors are elected and qualified:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
Joseph H. Capper
26,350,209

 
339,012

 
28,450

 
3,263,557

Joseph A. Frick
26,337,720

 
322,296

 
57,655

 
3,263,557

Colin Hill
26,010,487

 
649,751

 
57,433

 
3,263,557

Proposal 2
Vote on an advisory resolution to approve the compensation of the Company’s named executive officers:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
 
26,178,407

 
488,100

 
51,164

 
3,263,557

Proposal 3
Approval of the BioTelemetry, Inc. Amended and Restated 2017 Employee Stock Purchase Plan:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
 
26,649,891

 
46,820

 
20,960

 
3,263,557

Proposal 4
Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020:
 
 
 
 
 
 
 
Broker
 
For
 
Against
 
Abstained
 
Non-Vote
 
29,097,005

 
870,349

 
13,874

 







SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
BioTelemetry, Inc.
 
 
 
 
 
 
 
 
Dated: May 11, 2020
 
By:
/s/ Heather C. Getz
 
 
 
 
 
 
 
Name:
Heather C. Getz, CPA
 
 
 
Title:
Executive Vice President, Chief Financial and Administrative Officer